Pfizer stock: Bourla targets growth beyond patent losses
Published on 11/17/2026 at 17:15 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSPfizer's next growth phase
- Albert Bourla outlined a strategy for navigating patent losses through 2028 and pursuing high single-digit growth afterward.
- Newly launched products, cost savings and clinical programs are central to Pfizer's plan.
- Investors will watch pipeline readouts, oncology progress and delivery of the savings program.
Pfizer stock traded at 25.89 euros on Lang & Schwarz at 17:05 CET on Tuesday, November 17, 2026. Since the November 16 report, the quote was down 1.11 percent. The move came as CEO Albert Bourla presented Pfizer's strategy for navigating patent losses and returning to growth beyond 2028.
At the Jefferies Global Healthcare Conference on Tuesday, Bourla said recently launched products were growing 32 percent year over year and had reached an annualized revenue run rate of 15 billion to 16 billion US dollars. The figures point to the role of newer medicines as older franchises approach loss of exclusivity.
Cost savings and pipeline execution
Pfizer has achieved 7.2 billion US dollars in net savings and has announced a further 1.5 billion US dollars in reductions, according to the Reuters transcript published by Investing.com. Bourla also said Pfizer had invested 80 billion US dollars in acquisitions since the pandemic to build platforms, products and development programs.
The company started 20 Phase III studies in 2026, nearly twice as many as in the previous year. Oncology programs, immunology and obesity treatments are among the areas that could determine whether Pfizer converts its pipeline into durable sales.
What investors should watch
Pfizer expects the loss-of-exclusivity period to continue through 2028 and is targeting high single-digit growth from 2028 to 2033. Bourla said market estimates understate the revenue potential beyond 2030, while upcoming clinical readouts could help narrow the valuation gap.
Execution remains the central issue for investors: new products must offset pressure on established medicines, while cost reductions must translate into sustained financial flexibility. The next milestones are pipeline results, oncology progress and delivery of the announced savings.
US equities provide the broader market context in the S&P 500.
Further company coverage is available in More news and analyses on Pfizer stock.
Pfizer Inc. at a glance
- Company: Pfizer Inc.
- ISIN: US7170811035
- Stock: Pfizer stock
- Quoted price: 25.89 euros on Tuesday, November 17, 2026, at 17:05 CET
- Trading venue: Lang & Schwarz
- Change since the November 16 report: down 1.11 percent from 26.18 euros
